Outcomes of patients with EGFR-mutant advanced NSCLC in a developing country in Southeast Asia

• Main Authors: How, Soon Hin, Chong, Kin Liam, Zainal Abidin, Muhammad 'Adil, Hasbullah, Harissa H, Lye, Mun Tho, Gwo, Fuang Ho, Muhamad Nor, Ibtisam, Yong, Kek Pang, Kean, Fatt Ho, Thiagarajan, Muthukkumaran, Ariffin, Roziana, Samsudin, Azlina, Omar, Azza, Sin, Nee Tan, Choo, Khoon Ong, Sing, Yang Soon, Mau, Ern Poh
• Format: Article
• Language: English
• Published: Dove Medical Press Ltd 2022
• Subjects: RC0254 Neoplasms. Tumors. Oncology (including Cancer)
• Online Access: http://irep.iium.edu.my/98376/13/98376_Outcomes%20of%20patients%20with%20EGFR-mutant.pdf; http://irep.iium.edu.my/98376/; https://www.dovepress.com/outcomes-of-patients-with-egfr-mutant-advanced-nsclc-in-a-developing-c-peer-reviewed-fulltext-article-CMAR
• Institution: Universiti Islam Antarabangsa Malaysia

Background: Although first- and second-generation EGFR TKIs are considered first-line treatment in EGFRm+ NSCLC, most patients develop resistance and progress, commonly, EGFR T790M mutation. The third-generation EGFR-TKI has demonstrated efficacy in patients with progressive disease harboring the...